231
Participants
Start Date
October 8, 2019
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
Cemiplimab
Cemiplimab administered intravenously
RP1
RP1 administered intratumorally
Memorial Sloan Kettering Cancer Center, New York
Charite Universitatsmedizin Berlin, Berlin
Hippocratio General Hospital of Athens, Athens
Attiko University Hospital, Athens
Andreas Syggros Hospital, Athens
Universitätsklinikum Eppendorf, Hamburg
CHU Besancon - Hopital Jean Minjoz, Besançon
University Of North Carolina at Chapel Hill, Chapel Hill
Prisma Health Cancer Institute, Greenville
Hospital Universitario Virgen de la Arrixaca, Murcia
Winship Cancer Institute of Emory University, Atlanta
Orlando Health UF Health Cancer Center, Orlando
University of Miami Health System, Miami
Moffitt McKinley Outpatient Center, Tampa
CHU de Grenoble - Hopital A Michallon, La Tronche
Ohio State University Comprehensive Cancer Center, Columbus
Universitatsklinikum Essen, Essen
Hospital General Universitario De Valencia, Valencia
CHRU de Lille, Lille
Universitatsklinikum Heidelberg: National Centre for Tumour Diseases (NCT), Heidelberg
Hospices Civils de Lyon, Pierre-Bénite
Centre Léon Bérard, Lyon
Universitatsklinikum Tubingen Zentrum fur Dermatoonkologie, Tübingen
MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Aurora
University Hospital Munchen (LMU), München
University of California Los Angeles, Los Angeles
University of California San Diego, La Jolla
Stanford University, Stanford
Institut Gustave Roussy, Villejuif
John Theurer Cancer Center at Hackensack Univeristy Medical Center, Hackensack
Chris O'Brien Lifehouse, Camperdown
Cancer Care Wollongong Pty Limited, Wollongong
Tasman Oncology Research Ltd, Southport
Monash Medical Centre, Clayton
Peter MacCallum Cancer Centre, Melbourne
The Alfred Hospital, Melbourne
Sir Charles Gairdner Hospital, Nedlands
"Multiprofile Hospital for Active Treatment - Uni Hospital OOD Department of Medical Oncology", Panagyurishte
"Complex Oncology Center - Plovdiv EOOD Department of Medical Oncology and Cutaneous Cancer Diseases ", Plovdiv
CHU Dijon Hopital F. Mitterrand Service de Dermatologie - UMAC, Dijon
Service de Dermatologie et Cancerologie Cutanee Hopital de la Timone, Marseille
Hospital Saint Louis, Paris
"General Hospital of Athens Laiko, 1st Department of Medicine, University of Athens Medical School", Athens
"Istituto Tumori Giovanni Paolo II IRCCS", Bari
Klinika Dermatologii, Wenerologii i Alergologii, USK im J. Mikulicza-Radeckiego we Wroclawiu, Wroclaw
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Clinica Universitaria de Navarra, Pamplona
Sunnybrook Health Science Centre, Toronto
CHU Nice - Hopital de l'Archet 2, Nice
Uniwersyteckie Centrum Kliniczne; Centrum Leczenia Czerniaka w Gdańsku, Gdansk
Narodowy Instytut Onkologii; Panstwowy Instytut Badawczy Oddzial w Krakowie, Krakow
Narodowy Instytut Onkologii; Panstwowy Instytut Badawczy, Warsaw
Hospital Clinic Barcelona, Barcelona
Regeneron Pharmaceuticals
INDUSTRY
Replimune Inc.
INDUSTRY